Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metabolife execs subpoenaed

This article was originally published in The Tan Sheet

Executive Summary

House Energy & Commerce Subcommittee on Oversight & Investigations authorizes issuance of three subpoenas to former and current Metabolife employees in 9-0 vote. During business meeting held July 10, Rep. Greg Walden (R-Ore.) noted that in response to hearing invitation letters sent to 13 individuals, three Metabolife witnesses "have sent written responses through their respective counsels declining the invitation to testify." Founder, co-owner and former president Michael Ellis, former president David Brown and current employee Daniel Rodriguez will be issued subpoenas "as quickly as possible," committee says. In response, Metabolife maintains it is cooperating with House investigation and "looks forward to having its senior officials, including" CEO Russell Schreck, testify. First of two hearings on ephedra is scheduled for July 23; House inquiry began in February (1"The Tan Sheet" March 3, 2003, p. 9)...

You may also be interested in...



Ephedra hearings

House Energy & Commerce Committee/Subcommittee on Oversight & Investigations plans second day of hearings on botanical July 24, following previously-announced July 23 session (1"The Tan Sheet" July 14, 2003, In Brief). Hearings will take place in room 2123 in the Rayburn office building...

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel